Open AccessInitial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension*1
Author(s) -
Kenneth Jamerson,
Oliseyenum M. Nwose,
Lisa Jean-Louis,
Lesley Schofield,
Das Purkayastha,
Michelle A. Baron
Publication year - 2004
Publication title -
american journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.009
H-Index - 136
eISSN - 1941-7225
pISSN - 0895-7061
DOI - 10.1016/j.amjhyper.2004.02.003
Subject(s) - amlodipine , medicine , combination therapy , blood pressure , calcium channel blocker , benazepril , randomized controlled trial , urology
The Seventh Report of the Joint National Committee (JNC 7) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends initial combination therapy for patients whose blood pressure (BP) is >20/10 mm Hg above goal. This study evaluated the efficacy and safety of initial combination therapy versus that of monotherapy in patients with stage 2 hypertension, who by definition meet the JNC 7 recommendation for initial combination antihypertensive therapy.